company background image
000907582 logo

Amgen BRSE:000907582 Stock Report

Last Price

CHF 226.36

Market Cap

CHF 126.8b

7D

0%

1Y

n/a

Updated

03 Dec, 2023

Data

Company Financials +

Amgen Inc.

BRSE:000907582 Stock Report

Market Cap: CHF 126.8b

000907582 Stock Overview

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. More details

000907582 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance5/6
Financial Health2/6
Dividends5/6

Rewards

Trading at 49% below our estimate of its fair value

Earnings are forecast to grow 5.73% per year

Earnings grew by 10.7% over the past year

Pays a reliable dividend of 3.13%

Risk Analysis

Shares are highly illiquid

Debt is not well covered by operating cash flow

Significant insider selling over the past 3 months


My Notes

Capture your thoughts, links and company narrative

Amgen Inc. Competitors

Novartis

SWX:NOVN

CHF 173.4b

Roche Holding

SWX:ROG

CHF 198.6b

Lonza Group

SWX:LONN

CHF 38.4b

AbbVie

NYSE:ABBV

US$310.3b

Price History & Performance

Summary of share price highs, lows and changes for Amgen
Historical stock prices
Current Share PriceUS$226.36
52 Week HighUS$240.08
52 Week LowUS$198.51
Beta0.58
1 Month Change0%
3 Month Change-0.51%
1 Year Changen/a
3 Year Change25.87%
5 Year Change11.40%
Change since IPO186.53%

Recent News & Updates

Recent updates

Shareholder Returns

000907582CH BiotechsCH Market
7D0%-0.7%-2.3%
1Yn/a89.3%0.7%

Return vs Industry: Insufficient data to determine how 000907582 performed against the Swiss Biotechs industry.

Return vs Market: Insufficient data to determine how 000907582 performed against the Swiss Market.

Price Volatility

Is 000907582's price volatile compared to industry and market?
000907582 volatility
000907582 Average Weekly Movementn/a
Biotechs Industry Average Movement12.6%
Market Average Movement3.2%
10% most volatile stocks in CH Market7.4%
10% least volatile stocks in CH Market1.6%

Stable Share Price: 000907582 has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine 000907582's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
198025,200Bob Bradwaywww.amgen.com

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company’s products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

Amgen Inc. Fundamentals Summary

How do Amgen's earnings and revenue compare to its market cap?
000907582 fundamental statistics
Market capCHF 126.76b
Earnings (TTM)CHF 6.58b
Revenue (TTM)CHF 23.33b

19.3x

P/E Ratio

5.4x

P/S Ratio

Is 000907582 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
000907582 income statement (TTM)
RevenueUS$26.83b
Cost of RevenueUS$7.05b
Gross ProfitUS$19.78b
Other ExpensesUS$12.22b
EarningsUS$7.57b

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)14.14
Gross Margin73.73%
Net Profit Margin28.20%
Debt/Equity Ratio789.8%

How did 000907582 perform over the long term?

See historical performance and comparison

Dividends

3.1%

Current Dividend Yield

59%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/12/03 06:19
End of Day Share Price 2023/09/05 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Amgen Inc. is covered by 66 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Brian SkorneyBaird
Ishan MajumdarBaptista Research